Prognostic Impact of PMI in Stable CAD Undergoing PCI
The Prognostic Impact of Periprocedural Myocardial Injury in Stable Coronary Artery Disease Patients Undergoing Elective Percutaneous Coronary Intervention
1 other identifier
observational
2,000
1 country
1
Brief Summary
This is a single-center, observational, prospective study. This study aims to observe the effect of periprocedural myocardial injury on cardiovascular events in patients undergoing elective percutaneous coronary intervention, and to detect the levels of serum inflammatory factors before and after intervention to predict the occurrence of periprocedural myocardial injury and its association with cardiovascular events.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
January 20, 2020
CompletedFirst Posted
Study publicly available on registry
January 27, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2021
CompletedJanuary 27, 2020
January 1, 2020
3.9 years
January 20, 2020
January 20, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Major cardiac events
cardiac death, target vessel revascularization, target lesion revascularization, non-fatal myocardial infarction, heart failure, angina pectoris
12 months after PCI
Secondary Outcomes (1)
Serum level of inflammatory factors
1 day after PCI
Study Arms (2)
PMI
non-PMI
Eligibility Criteria
In-patients with stable coronary artery disease undergoing elective percutaneous coronary intervention in Zhongshan Hospital will be enrolled.
You may qualify if:
- underwent elective coronary stenting
- patients permit informed consents
You may not qualify if:
- acute STEMI
- NYHA class III-IV heart failure
- moderate-to-severe valvular disease
- missing post-PCI troponin results
- active infection, respiratory failure
- liver dysfunction (liver enzyme \>3xURL or bilirubin \>2xURL),
- malignancy and systemic connective tissue disease
- unable to get a informed consents
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
180 Fenglin Road
Shanghai, Shanghai Municipality, 200032, China
Biospecimen
Blood samples of the participants before and after percutaneous coronary intervention therapy were selected.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 20, 2020
First Posted
January 27, 2020
Study Start
January 1, 2017
Primary Completion
December 1, 2020
Study Completion
May 1, 2021
Last Updated
January 27, 2020
Record last verified: 2020-01
Data Sharing
- IPD Sharing
- Will not share